{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:49:10Z","timestamp":1767138550299,"version":"build-2238731810"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/bf03261877","type":"journal-article","created":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T05:14:54Z","timestamp":1357535694000},"page":"431-440","source":"Crossref","is-referenced-by-count":3,"title":["Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome"],"prefix":"10.1007","volume":"10","author":[{"given":"Michael","family":"Eaddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Seal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Tangirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hackney Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"O\u2019Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"1877_CR1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2006.09.005","volume":"18","author":"C. Gemici","year":"2006","unstructured":"Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006; 18: 773\u201380","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1877_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00860751","volume":"9","author":"D.P. Jones","year":"1995","unstructured":"Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9: 206\u201312","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1877_CR3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","volume":"98","author":"A. Bosley","year":"2003","unstructured":"Bosley A, Snoet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. Cancer 2003; 98(5): 1048\u201354","journal-title":"Cancer"},{"issue":"3","key":"1877_CR4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"C. Pui","year":"2001","unstructured":"Pui C, Hazem HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19(3): 697\u2013704","journal-title":"J Clin Oncol"},{"key":"1877_CR5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","volume":"15","author":"C. Pui","year":"2001","unstructured":"Pui C, Jeha S, Irwin D, et al. Recombinant urate oxidase in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505\u20139","journal-title":"Leukemia"},{"key":"1877_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2402847","volume":"17","author":"P.M. Navolonic","year":"2003","unstructured":"Navolonic PM, Pui C, Larson RA, et al. Elitek\u2122\u2014 rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas, Texas, January 2002. Leukemia 2003; 17: 499\u2013514","journal-title":"Leukemia"},{"issue":"2","key":"1877_CR7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","volume":"36","author":"T.I. Mughal","year":"2010","unstructured":"Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010 Apr; 36(2): 164\u201376","journal-title":"Cancer Treat Rev"},{"key":"1877_CR8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJM197008132830708","volume":"283","author":"P.R. Band","year":"1970","unstructured":"Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283: 354\u20137","journal-title":"N Engl J Med"},{"key":"1877_CR9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0022-3476(86)80387-0","volume":"109","author":"S.P. Andreoli","year":"1986","unstructured":"Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109: 292\u20138","journal-title":"J Pediatr"},{"key":"1877_CR10","first-page":"47","volume":"22","author":"J. Monballyu","year":"1984","unstructured":"Monballyu J, Zachee P, Verberckmoes R, et al. Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt\u2019s lymphoma. Clin Nephrol 1984; 22: 47\u201350","journal-title":"Clin Nephrol"},{"key":"1877_CR11","first-page":"890","volume":"17","author":"J.M. Brogard","year":"1972","unstructured":"Brogard JM, Coumaros D, Franckhauser J, et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etudes Clin Biol 1972; 17: 890\u20135","journal-title":"Rev Eur Etudes Clin Biol"},{"key":"1877_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","volume":"19","author":"S. Jeha","year":"2005","unstructured":"Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek\u2122), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19: 34\u20138","journal-title":"Leukemia"},{"key":"1877_CR13","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"B. Coiffier","year":"2003","unstructured":"Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402\u20136","journal-title":"J Clin Oncol"},{"key":"1877_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdf134","volume":"13","author":"C. Patte","year":"2002","unstructured":"Patte C, Sakiroglu C, Ansoborlo A, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol. Ann Oncol 2002; 13: 789\u201395","journal-title":"Ann Oncol"},{"issue":"1","key":"1877_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLM.2008.n.003","volume":"8","author":"S. Candrilli","year":"2008","unstructured":"Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without renal failure. Clin Lymphoma Myeloma 2008; 8(1): 44\u201351","journal-title":"Clin Lymphoma Myeloma"},{"issue":"24","key":"1877_CR16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2146\/ajhp100022","volume":"67","author":"M. Eaddy","year":"2010","unstructured":"Eaddy M, Seal B, Tangirala M, et al. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. Am J Health Syst Pharm 2010 Dec; 67(24): 2110\u20134","journal-title":"Am J Health Syst Pharm"},{"key":"1877_CR17","unstructured":"ELITEK\u00ae [package insert]. Bridgewater (NJ): sanofi-aventis, June 2008"},{"issue":"9","key":"1877_CR18","first-page":"25","volume":"44","author":"M. Solh","year":"2008","unstructured":"Solh M, Appel J. Tumor lysis syndrome. Hosp Physician 2008; 44(9): 25\u20139","journal-title":"Hosp Physician"},{"key":"1877_CR19","unstructured":"RedBook Online\u00ae, Thomson Reuters (Healthcare) Inc. Available from URL: http:\/\/www.thomsonhc.com [Accessed 2012 Jul 23]"},{"key":"1877_CR20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","volume":"37","author":"S. Trifilio","year":"2006","unstructured":"Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37: 997\u20131001","journal-title":"Bone Marrow Transplant"},{"key":"1877_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000089463","volume":"115","author":"L. Wang","year":"2006","unstructured":"Wang L, Shih L, Chang H, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006; 115: 35\u20138","journal-title":"Acta Haematol"},{"key":"1877_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2008.00994.x","volume":"34","author":"M. Campara","year":"2009","unstructured":"Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009; 34: 207\u201313","journal-title":"J Clin Pharm Ther"},{"key":"1877_CR23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0609.2005.00550.x","volume":"75","author":"M. Hummel","year":"2005","unstructured":"Hummel M, Buchheidt D, Reiter S, et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia: successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005; 75: 518\u201321","journal-title":"Eur J Haematol"},{"key":"1877_CR24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","volume":"26","author":"D.A. Hutcherson","year":"2006","unstructured":"Hutcherson DA, Gammon DC, Bhatt MS, et al. Reduceddose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26: 242\u20137","journal-title":"Pharmacotherapy"},{"key":"1877_CR25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","volume":"29","author":"C.Y. Liu","year":"2005","unstructured":"Liu CY, Sims-McCallum RP, Schiffer C. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leukemia Res 2005; 29: 463\u20135","journal-title":"Leukemia Res"},{"key":"1877_CR26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","volume":"26","author":"A.M. McDonnell","year":"2006","unstructured":"McDonnell AM, Lenz KL, Frei-Lahr DA, et al. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006; 26: 806\u201312","journal-title":"Pharmacotherapy"},{"key":"1877_CR27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E002","volume":"38","author":"T.M. Arnold","year":"2004","unstructured":"Arnold TM, Reuter JP, Delman BS, et al. Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004; 38: 1428\u201331","journal-title":"Ann Pharmacother"},{"key":"1877_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00520-002-0435-3","volume":"11","author":"L. Annemans","year":"2003","unstructured":"Annemans L, Moeremans K, Lamotte M, et al. Pan-European mul ticentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 11: 249\u201357","journal-title":"Support Care Cancer"},{"key":"1877_CR29","unstructured":"Xcenda. Elitek hospital model. Developed October 2009. On file with sanofi-aventis"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03261877\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T20:26:31Z","timestamp":1595190391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03261877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":29,"aliases":["10.2165\/11634230-000000000-00000"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/bf03261877","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}